Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Heart Failure Reviews
Published in: Heart Failure Reviews 3/2016

01-05-2016

Pulmonary hypertension associated with lung diseases and hypoxemia

Author: Michael J. Cuttica

Published in: Heart Failure Reviews | Issue 3/2016

Login to get access

Abstract

Pulmonary hypertension that develops in the setting of underlying lung diseases such as COPD or idiopathic pulmonary fibrosis (IPF) is associated with decreased functional status, worsening hypoxemia and quality of life, and increased mortality. This complication of lung disease is complex in its origin and carries a unique set of diagnostic and therapeutic issues. This review attempts to provide an overview of mechanisms associated with the onset of pulmonary hypertension in COPD and IPF, touches on appropriate evaluation, and reviews the state of knowledge on treating pulmonary hypertension related to underlying lung disease.
Literature
1.
Hoeper MM, Bogaard HJ, Condliffe R et al (2013) Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D42–D50CrossRefPubMed
2.
3.
Simonneau G, Gatzoulis MA, Adatia I et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34–D41CrossRefPubMed
4.
Cuttica MJ, Kalhan R, Shlobin OA et al (2010) Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 104(12):1877–1882CrossRefPubMed
5.
Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF (2006) Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129(3):746–752CrossRefPubMed
6.
Thabut G, Dauriat G, Stern JB et al (2005) Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 127(5):1531–1536CrossRefPubMed
7.
Chaouat A, Bugnet AS, Kadaoui N et al (2005) Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172(2):189–194CrossRefPubMed
8.
Andersen CU, Mellemkjaer S, Nielsen-Kudsk JE, Bendstrup E, Hilberg O, Simonsen U (2013) Pulmonary hypertension in chronic obstructive and interstitial lung diseases. Int J Cardiol 168(3):1795–1804CrossRefPubMed
9.
Farkas L, Gauldie J, Voelkel NF, Kolb M (2011) Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol 45(1):1–15CrossRefPubMed
10.
Scharf SM, Iqbal M, Keller C et al (2002) Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 166(3):314–322CrossRefPubMed
11.
Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A (1985) Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 131(4):493–498PubMed
12.
Timms RM, Khaja FU, Williams GW (1985) Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med 102(1):29–36CrossRefPubMed
13.
Wright JL, Petty T, Thurlbeck WM (1992) Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung 170(2):109–124CrossRefPubMed
14.
Magee F, Wright JL, Wiggs BR, Pare PD, Hogg JC (1988) Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax 43(3):183–189CrossRefPubMedPubMedCentral
15.
Santos S, Peinado VI, Ramirez J et al (2002) Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 19(4):632–638CrossRefPubMed
16.
Seimetz M, Parajuli N, Pichl A et al (2011) Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 147(2):293–305CrossRefPubMed
17.
Barbera JA, Riverola A, Roca J et al (1994) Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 149(2 Pt 1):423–429CrossRefPubMed
18.
Elbehairy AF, Ciavaglia CE, Webb KA et al (2015) Pulmonary gas exchange abnormalities in mild chronic obstructive pulmonary disease. Implications for dyspnea and exercise intolerance. Am J Respir Crit Care Med 191(12):1384–1394CrossRefPubMed
19.
Cuttica MJ, Shah SJ, Rosenberg SR et al (2011) Right heart structural changes are independently associated with exercise capacity in non-severe COPD. PLoS One 6(12):e29069CrossRefPubMedPubMedCentral
20.
Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD (2007) Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 82(3):342–350CrossRefPubMed
21.
Nathan SD, Noble PW, Tuder RM (2007) Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 175(9):875–880CrossRefPubMed
22.
Ebina M, Shimizukawa M, Shibata N et al (2004) Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 169(11):1203–1208CrossRefPubMed
23.
Cosgrove GP, Brown KK, Schiemann WP et al (2004) Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 170(3):242–251CrossRefPubMed
24.
Chaouat A, Savale L, Chouaid C et al (2009) Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 136(3):678–687CrossRefPubMed
25.
Kwon YS, Chi SY, Shin HJ et al (2010) Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Korean Med Sci 25(10):1487–1491CrossRefPubMedPubMedCentral
26.
Peinado VI, Pizarro S, Barbera JA (2008) Pulmonary vascular involvement in COPD. Chest 134(4):808–814CrossRefPubMed
27.
Karmouty-Quintana H, Philip K, Acero LF et al (2015) Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension. FASEB J 29(1):50–60CrossRefPubMedPubMedCentral
28.
Peinado VI, Barbera JA, Ramirez J et al (1998) Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol 274(6 Pt 1):L908–L913PubMed
29.
Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q (1993) Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 341(8860):1550–1554CrossRefPubMed
30.
Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ (2004) Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 59(7):581–585CrossRefPubMedPubMedCentral
31.
Renzoni EA, Walsh DA, Salmon M et al (2003) Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 167(3):438–443CrossRefPubMed
32.
33.
Oswald-Mammosser M, Weitzenblum E, Quoix E et al (1995) Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 107(5):1193–1198CrossRefPubMed
34.
Andersen KH, Iversen M, Kjaergaard J et al (2012) Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant 31(4):373–380CrossRefPubMed
35.
D’Alonzo GE, Barst RJ, Ayres SM et al (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115(5):343–349CrossRefPubMed
36.
Benza RL, Gomberg-Maitland M, Miller DP et al (2012) The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest 141(2):354–362CrossRefPubMed
37.
Humbert M, Sitbon O, Chaouat A et al (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122(2):156–163CrossRefPubMed
38.
Stone AC, Machan JT, Mazer J, Casserly B, Klinger JR (2011) Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease. Lung 189(3):207–212CrossRefPubMed
39.
Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E (1999) Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159(1):158–164CrossRefPubMed
40.
Seeger W, Adir Y, Barbera JA et al (2013) Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 62(25 Suppl):D109–D116CrossRefPubMed
41.
42.
Badano LP, Ginghina C, Easaw J et al (2010) Right ventricle in pulmonary arterial hypertension: haemodynamics, structural changes, imaging, and proposal of a study protocol aimed to assess remodelling and treatment effects. Eur J Echocardiogr. 11(1):27–37CrossRefPubMed
43.
Falk JA, Kadiev S, Criner GJ, Scharf SM, Minai OA, Diaz P (2008) Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5(4):543–548CrossRefPubMedPubMedCentral
44.
Fisher MR, Criner GJ, Fishman AP et al (2007) Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 30(5):914–921CrossRefPubMed
45.
Badesch DB, Champion HC, Sanchez MA et al (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54(1 Suppl):S55–S66CrossRefPubMed
46.
Devaraj A, Wells AU, Meister MG, Corte TJ, Hansell DM (2008) The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. Radiology 249(3):1042–1049CrossRefPubMed
47.
Nadrous HF, Pellikka PA, Krowka MJ et al (2005) The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest 128(6 Suppl):616S–617SCrossRefPubMed
48.
Hamada K, Nagai S, Tanaka S et al (2007) Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 131(3):650–656CrossRefPubMed
49.
Kimura M, Taniguchi H, Kondoh Y et al (2013) Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration 85(6):456–463CrossRefPubMed
50.
Behr J, Ryu JH (2008) Pulmonary hypertension in interstitial lung disease. Eur Respir J 31(6):1357–1367CrossRefPubMed
51.
Nathan SD, Shlobin OA, Ahmad S et al (2008) Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 76(3):288–294CrossRefPubMed
52.
Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD (2007) Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 30(4):715–721CrossRefPubMed
53.
Andersen CU, Mellemkjaer S, Hilberg O, Nielsen-Kudsk JE, Simonsen U, Bendstrup E (2012) Pulmonary hypertension in interstitial lung disease: prevalence, prognosis and 6 min walk test. Respir Med 106(6):875–882CrossRefPubMed
54.
Modrykamien AM, Gudavalli R, McCarthy K, Parambil J (2010) Echocardiography, 6-min walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis. Respir Care 55(5):584–588PubMed
55.
Swigris JJ, Olson AL, Shlobin OA, Ahmad S, Brown KK, Nathan SD (2011) Heart rate recovery after 6-min walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology 16(3):439–445CrossRefPubMedPubMedCentral
56.
Patel NM, Lederer DJ, Borczuk AC, Kawut SM (2007) Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 132(3):998–1006CrossRefPubMed
57.
58.
Chaouat A, Weitzenblum E, Krieger J, Oswald M, Kessler R (1996) Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest 109(2):380–386CrossRefPubMed
59.
Minai OA, Ricaurte B, Kaw R et al (2009) Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 104(9):1300–1306CrossRefPubMed
60.
Bady E, Achkar A, Pascal S, Orvoen-Frija E, Laaban JP (2000) Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax 55(11):934–939CrossRefPubMedPubMedCentral
61.
Niijima M, Kimura H, Edo H et al (1999) Manifestation of pulmonary hypertension during REM sleep in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 159(6):1766–1772CrossRefPubMed
62.
Sajkov D, Wang T, Saunders NA, Bune AJ, Neill AM (1999) Douglas Mcevoy R. Daytime pulmonary hemodynamics in patients with obstructive sleep apnea without lung disease. Am J Respir Crit Care Med 159(5 Pt 1):1518–1526CrossRefPubMed
63.
Sanner BM, Doberauer C, Konermann M, Sturm A, Zidek W (1997) Pulmonary hypertension in patients with obstructive sleep apnea syndrome. Arch Intern Med 157(21):2483–2487CrossRefPubMed
64.
Laks L, Lehrhaft B, Grunstein RR, Sullivan CE (1995) Pulmonary hypertension in obstructive sleep apnoea. Eur Respir J 8(4):537–541PubMed
65.
Kessler R, Chaouat A, Schinkewitch P et al (2001) The obesity-hypoventilation syndrome revisited: a prospective study of 34 consecutive cases. Chest 120(2):369–376CrossRefPubMed
66.
Sugerman HJ, Baron PL, Fairman RP, Evans CR, Vetrovec GW (1988) Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss. Ann Surg 207(5):604–613CrossRefPubMedPubMedCentral
67.
Ahmed Q, Chung-Park M, Tomashefski JF Jr (1997) Cardiopulmonary pathology in patients with sleep apnea/obesity hypoventilation syndrome. Hum Pathol 28(3):264–269CrossRefPubMed
68.
Atwood CW Jr, McCrory D, Garcia JG, Abman SH, Ahearn GS (2004) Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. Chest 126(1 Suppl):72S–77SCrossRefPubMed
69.
Arias MA, Garcia-Rio F, Alonso-Fernandez A, Martinez I, Villamor J (2006) Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J 27(9):1106–1113CrossRefPubMed
70.
Colish J, Walker JR, Elmayergi N et al (2012) Obstructive sleep apnea: effects of continuous positive airway pressure on cardiac remodeling as assessed by cardiac biomarkers, echocardiography, and cardiac MRI. Chest 141(3):674–681CrossRefPubMed
71.
Sajkov D, Wang T, Saunders NA, Bune AJ, McEvoy RD (2002) Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 165(2):152–158CrossRefPubMed
72.
Phillips BG, Narkiewicz K, Pesek CA, Haynes WG, Dyken ME, Somers VK (1999) Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 17(1):61–66CrossRefPubMed
73.
Yokoe T, Minoguchi K, Matsuo H et al (2003) Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107(8):1129–1134CrossRefPubMed
74.
Celli BR, MacNee W (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23(6):932–946CrossRefPubMed
75.
Vestbo J, Hurd SS, Agusti AG et al (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187(4):347–365CrossRefPubMed
76.
Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824CrossRefPubMed
77.
Finlay M, Middleton HC, Peake MD, Howard P (1983) Cardiac output, pulmonary hypertension, hypoxaemia and survival in patients with chronic obstructive airways disease. Eur J Respir Dis 64(4):252–263PubMed
78.
Medical Research Council Working Party (1981) Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1(8222):681–686
79.
Nocturnal Oxygen Therapy Working Group (1980) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 93(3):391–398CrossRef
80.
Zielinski J, Tobiasz M, Hawrylkiewicz I, Sliwinski P, Palasiewicz G (1998) Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. Chest 113(1):65–70CrossRefPubMed
81.
McNicholas WT, Verbraecken J, Marin JM (2013) Sleep disorders in COPD: the forgotten dimension. Eur Respir Rev Off J Eur Respir Soc 22(129):365–375CrossRef
82.
Stolz D, Rasch H, Linka A et al (2008) A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 32(3):619–628CrossRefPubMed
83.
Valerio G, Bracciale P, Grazia D’Agostino A (2009) Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 3(1):15–21CrossRefPubMed
84.
King TE Jr, Brown KK, Raghu G et al (2011) BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184(1):92–99CrossRefPubMed
85.
Raghu G, Behr J, Brown KK et al (2013) Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 158(9):641–649CrossRefPubMed
86.
Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J (2013) Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J 42(6):1622–1632CrossRefPubMed
87.
Corte TJ, Keir GJ, Dimopoulos K et al (2014) Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med 190(2):208–217CrossRefPubMedPubMedCentral
88.
Blanco I, Gimeno E, Munoz PA et al (2010) Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 181(3):270–278CrossRefPubMed
89.
Rietema H, Holverda S, Bogaard HJ et al (2008) Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 31(4):759–764CrossRefPubMed
90.
Lederer DJ, Bartels MN, Schluger NW et al (2012) Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD 9(3):268–275CrossRefPubMed
91.
Holverda S, Rietema H, Bogaard HJ et al (2008) Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulm Pharmacol Ther 21(3):558–564CrossRefPubMed
92.
Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW (2010) A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 363(7):620–628CrossRefPubMed
93.
Han MK, Bach DS, Hagan PG et al (2013) Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest 143(6):1699–1708CrossRefPubMedPubMedCentral
94.
Ghofrani HA, D’Armini AM, Grimminger F et al (2013) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369(4):319–329CrossRefPubMed
95.
Ghofrani HA, Galie N, Grimminger F et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369(4):330–340CrossRefPubMed
96.
Archer SL, Mike D, Crow J, Long W, Weir EK (1996) A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 109(3):750–755CrossRefPubMed
97.
Hegewald MJ, Elliott CG (2009) Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension. Chest 135(2):536–537CrossRefPubMed
98.
Dernaika TA, Beavin M, Kinasewitz GT (2010) Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respir Int Rev Thorac Dis 79(5):377–382
99.
Olschewski H, Ghofrani HA, Walmrath D et al (1999) Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 160(2):600–607CrossRefPubMed
100.
Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD (2013) Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest 144(1):169–176CrossRefPubMed
Metadata
Title
Pulmonary hypertension associated with lung diseases and hypoxemia
Author
Michael J. Cuttica
Publication date
01-05-2016
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 3/2016
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-016-9551-x

Other articles of this Issue 3/2016

Heart Failure Reviews 3/2016 Go to the issue

OriginalPaper

Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation

OriginalPaper

Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure

OriginalPaper

Classification and diagnosis of pulmonary hypertension

OriginalPaper

The right ventricle and pulmonary hypertension

OriginalPaper

Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction

OriginalPaper

Molecular pathogenesis and current pathology of pulmonary hypertension

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits